Predictive Oncology Inc. POAI Archives - Page 17 of 19

ThursdayDec 05, 2019 11:08 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Multiple Indications of Interest for Skyline Medical Division

Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its receipt of interest from several parties for the possible acquisition of its Skyline Medical division, which produces and sells the STREAMWAY System for disposal of fluids in medical applications. Predictive Oncology previously announced intentions to focus its resources on its primary mission of applying artificial intelligence to precision medicine and drug discovery. “I am exceptionally pleased with the rapid growth and development of our Helomics and Tumor Genesis divisions, as well as the multiple indications of interest for our Skyline Medical…

WednesdayDec 04, 2019 2:44 pm

QualityStocksNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Platform Revolutionizing Cancer Treatment

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven, precision-medicine company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery. An article discussing the company reads, “POAI’s platform, composed of over 150,000 patient tumors, harnesses the power of an individual patient’s tumor to help recommend the best treatment for that patient. This database, which houses evidence documenting actual drug responses of cancer patients’ individual tumors, uses artificial intelligence to create a valuable predictive tool for pharmaceutical companies and researchers. . . . Industry leaders believe that models utilizing patient-derived data powered by artificial intelligence will allow doctors to make…

MondayNov 25, 2019 3:52 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its recent receipt of notification (the “Notification Letter on Compliance”) from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (the “Nasdaq”) that indicates Predictive Oncology has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Minimum Bid Price Requirement”). Per the update, Predictive Oncology received, on November 16, 2018, notification from the Nasdaq (the “Notification Letter on Deficiency”) indicating that the closing bid price per share had been below $1.00…

WednesdayNov 20, 2019 2:43 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $15 Million Equity Line

Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into a $15 million common stock purchase and registration rights agreement with Oasis Capital, LLC, a Puerto Rico limited liability company. Under the agreement, upon satisfaction of its conditions including the effectiveness of a resale registration statement, which has occurred, Predictive Oncology has the right to sell up to $15 million of its common stock to Oasis Capital over a 36-month period. “With this equity line established, the financial road ahead for Predictive Oncology has truly begun to smooth out,“…

TuesdayNov 19, 2019 12:44 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Technology May Prove Critical in New Cancer Drug Development

Predictive Oncology subsidiary TumorGenesis developing new PDx models needed to understand the complexities of cancer Tremendous unmet need for patient-derived tumors (PDx) for new drug development - current mouse models unreliable TumorGenesis unique in the industry; its ovarian-cancer cells haven’t been widely available like most other PDx samples Multi-billion-dollar market opportunity As the precision-medicine industry continues to integrate technology to improve the efficiency and efficacy of its strategies, clinicians are realizing the need for actual patient samples to determine the best methods to defeat cancer. Researchers are now turning to patient-derived tumors (PDx) to better understand the complexities and vagaries…

TuesdayNov 19, 2019 11:31 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Corporate, Scientific Milestones in NetworkNewsAudio Interview

Predictive Oncology (NASDAQ: POAI), an artificial intelligence (“AI”) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products and services, this morning announced the broadcast of a NetworkNewsAudio (“NNA”) interview with Stuart Smith of NetworkNewsWire (“NNW”). Predictive Oncology CEO Dr. Carl Schwartz joined Smith to discuss several corporate and scientific milestones that have been achieved by the company in 2019, as well as POAI’s strategy moving forward. “Predictive Oncology and its subsidiaries, in collaboration with key players in the pharmaceutical, diagnostic and biotech industries, are finding success in…

MondayNov 18, 2019 9:59 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Reports Q3 Results, 58% Revenue Increase

Predictive Oncology (NASDAQ: POAI), an artificial intelligence (“AI”) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products and services, on Friday announced its financial results for the quarter ended September 30, 2019 and provided a business update. Among the highlights, the company reported a 58% year-over-year increase in revenue for the quarter ended September 30, 2019, to $522,696 compared with $329,930 for the same period last year. “I am very pleased with the growth and development of our unique assets, Helomics and Tumor Genesis, and the and…

FridayNov 15, 2019 1:45 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Harnessing the Power of Artificial Intelligence to Improve Clinical Outcomes

Predictive Oncology (NASDAQ: POAI), a knowledge-driven, precision-medicine company, applies its smart tumor profiling and artificial intelligence (“AI”) platform to extensive genomic and biomarker patient data sets to predict and improve clinical outcomes for cancer patients. An article discussing the company reads, “While precision medicine, sometimes referred to as personalized medicine, is a relatively new term, the idea has been around for years (http://ibn.fm/KlNJH). Defined by the U.S. National Library of Medicine as ‘an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person,’ the approach is gaining momentum as…

WednesdayNov 13, 2019 1:20 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) AI-Driven Predictive Models Better Inform Clinicians, Researchers; Changing Landscape of Cancer Treatment

POAI subsidiary Helomics announce sequencing of ovarian tumor cases from UPMC Magee collaboration, a critical step in strategic Cancer Quest 2020 initiative Data key to value in $48-billion precision-medicine industry Industry leaders such as POAI realize critical value in patient-specific, data-driven models The field of drug development for cancer treatment involves costly and time-intensive research. As technology plays an ever-increasing role in driving medicine, researchers and clinicians are discovering the significant potential of patient-derived models in matching specific cancer types with their most effective treatments. These models, which harness the patients’ own cancer cells to best determine how to defeat…

FridayNov 08, 2019 2:56 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Extensive Database, Artificial Intelligence to Identify Applicable Cancer Treatments

Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is utilizing the combined capabilities of AI with its extensive database of tumor data to assist clinicians in selecting the most effective drug treatments for cancer patients. An article discussing the company reads, “One disruptive aspect of POAI’s technology is that it helps the clinician to increase the chance of choosing more effective therapy, resulting in potential reduction of side-effects as well as cost savings. Traditionally oncologists prescribe what drugs they think have the best chance at beating a patient’s cancer, and the drug…

Site Search

Company Search

Tag: Predictive Oncology Inc. POAI